Scandion Oncology (Scandion) has received a favorable patentability opinion from the European Patent Office (EPO) on an international patent application aiming to further enhance the patent protection of Scandion's lead compound SCO-101. If granted, the patent will prolong the potential commercial exclusivity period for SCO-101. This could also allow Scandion to expand the development of SCO-101 into new indications and drug combinations, potentially making a future treatment available to more patients.

The international patent application relates to solid crystal forms of SCO-101. If granted, this Composition of Matter patent is envisaged to provide protection of the commercial solid form of SCO-101 until its expiry in 2042 or later.